A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites

被引:135
作者
Albillos, A [1 ]
Bañares, R
González, M
Catalina, MV
Molinero, LM
机构
[1] Univ Alcala de Henares, Serv Gastroenterol, Hosp Univ Ramon & Cajal, Dept Med, Madrid, Spain
[2] Univ Complutense, Gastroenterol Serv, Hosp Univ Gen Gregorio Maranon, Dept Med, E-28040 Madrid, Spain
[3] Alce Ingn, Madrid, Spain
关键词
cirrhosis; encephalopathy; pooled hazard ratio; inconsistency index; systematic review;
D O I
10.1016/j.jhep.2005.06.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Meta-analysis designed to provide evidence-based guidance on the effect of TIPS and paracentesis on mortality and encephalopathy in cirrhotic patients with refractory ascites. Methods: Five randomized trials published between 1989 and 2005 were identified. Results: The five trials involved 330 patients, and none included patients > 76 years, with bilirubin > 5-10 mg/dl or creatinine > 3 mg/dl. Ascites recurrence was lower in the TIPS arm (RR 0.56; 95 % CI 0.47-0.66). TIPS was associated with a greater risk of encephalopathy (RR 1.36; 95% CI 1.1-1.68) and severe encephalopathy (RR 1.72; 95% CI 1.142.58). TIPS did not affect mortality, as estimated by the RR (0.93; 95% CI 0.67-1.28, random effect model) and pooled hazard ratio (RR 1.09; 95% CI 0.84-1.88). Analysis of this outcome measure was limited by significant heterogeneity among trials. Liver-related mortality was homogenous and similar in both arms. Results were unaffected by excluding trials of lower quality or with a greater number of alcoholics. Meta-analysis of trials including patients with recidivant ascites revealed a lower mortality in the TIPS arm (RR 0.68; 95% CI 0.49-0.93). Conclusions: In patients with refractory ascites, a better control of ascites by TIPS does not translate into improved survival and worsens encephalopathy. (c) 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:990 / 996
页数:7
相关论文
共 27 条
[1]  
Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122
[2]   Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management [J].
Arroyo, V ;
Colmenero, J .
JOURNAL OF HEPATOLOGY, 2003, 38 :S69-S89
[3]   Transjugular intrahepatic portosystemic shunt: Current status [J].
Boyer, TD .
GASTROENTEROLOGY, 2003, 124 (06) :1700-1710
[4]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[5]   Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis [J].
Forrest, EH ;
Stanley, AJ ;
Redhead, DN ;
McGilchrist, AJ ;
Hayes, PC .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (05) :801-806
[6]   Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis [J].
Garcia-Tsao, G .
GASTROENTEROLOGY, 2001, 120 (03) :726-748
[7]  
GATTA A, 1991, HEPATOLOGY, V14, P231, DOI 10.1002/hep.1840140205
[8]   Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis [J].
Gines, A ;
FernandezEsparrach, G ;
Monescillo, A ;
Vila, C ;
Domenech, E ;
Abecasis, R ;
Angeli, P ;
RuizDelArbol, L ;
Planas, R ;
Sola, R ;
Gines, P ;
Terg, R ;
Inglada, L ;
Vaque, P ;
Salerno, F ;
Vargas, V ;
Clemente, G ;
Quer, JC ;
Jimenez, W ;
Arroyo, V ;
Rodes, J .
GASTROENTEROLOGY, 1996, 111 (04) :1002-1010
[9]   Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis [J].
Ginès, P ;
Uriz, J ;
Calahorra, B ;
Garcia-Tsao, G ;
Kamath, PS ;
Del Arbol, LR ;
Planas, R ;
Bosch, J ;
Arroyo, V ;
Rodés, J .
GASTROENTEROLOGY, 2002, 123 (06) :1839-1847
[10]   Quantifying heterogeneity in a meta-analysis [J].
Higgins, JPT ;
Thompson, SG .
STATISTICS IN MEDICINE, 2002, 21 (11) :1539-1558